Abstract | BACKGROUND: AIM: METHODS: RESULTS: Of the 22 patients enrolled, data of 19 patients were used for analysis. The adjusted mean serum phosphate levels at 12 weeks did not differ significantly between calcium acetate- (5.3 mg/dl) and sevelamer-treated subjects (6.1 mg/dl) (P adjusted means = 0.6). The adjusted blood level of calcium at 12 weeks was significantly lower in the sevelamer-treated patients (8.2 mg/dl) compared to those treated with calcium acetate (9.1 mg/dl) (P adjusted means = 0.01). In the sevelamer group, there was a non-significant decrease in serum bicarbonate, whereas the total and LDL cholesterol significantly decreased at 12 weeks (P = 0.04). Sevelamer hydrochloride was well tolerated and without adverse effects related to the drug. CONCLUSIONS:
|
Authors | Ashima Gulati, Vijesh Sridhar, Tathagata Bose, Pankaj Hari, Arvind Bagga |
Journal | International urology and nephrology
(Int Urol Nephrol)
Vol. 42
Issue 4
Pg. 1055-62
(Dec 2010)
ISSN: 1573-2584 [Electronic] Netherlands |
PMID | 20020207
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Acetates
- Calcium Compounds
- Chelating Agents
- Polyamines
- Sevelamer
- calcium acetate
|
Topics |
- Acetates
(therapeutic use)
- Calcium Compounds
(therapeutic use)
- Chelating Agents
(therapeutic use)
- Child
- Child, Preschool
- Chronic Disease
- Female
- Humans
- Kidney Diseases
(drug therapy)
- Male
- Polyamines
(therapeutic use)
- Sevelamer
- Severity of Illness Index
- Time Factors
|